These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 33933230)

  • 1. How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?
    Towse A; Chalkidou K; Firth I; Kettler H; Silverman R
    Value Health; 2021 May; 24(5):625-631. PubMed ID: 33933230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
    So AD; Woo J
    BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tiered pricing of vaccines: a win-win-win situation, not a subsidy.
    Plahte J
    Lancet Infect Dis; 2005 Jan; 5(1):58-63. PubMed ID: 15620562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic.
    Neumann PJ; Cohen JT; Kim DD; Ollendorf DA
    Health Aff (Millwood); 2021 Jan; 40(1):53-61. PubMed ID: 33211534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covid-19: an economic perspective on vaccinating the world.
    Donaldson C; Biosca O
    BMJ; 2021 Jun; 373():n1498. PubMed ID: 34130993
    [No Abstract]   [Full Text] [Related]  

  • 6. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of the Wealthiest?
    Garfinkel M; Sansonetti PJ; Pulverer B
    EMBO J; 2020 Dec; 39(23):e107227. PubMed ID: 33205839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis.
    Obeng-Kusi M; Erstad B; Roe DJ; Abraham I
    J Med Econ; 2022; 25(1):894-902. PubMed ID: 35748085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.
    Wouters OJ; Shadlen KC; Salcher-Konrad M; Pollard AJ; Larson HJ; Teerawattananon Y; Jit M
    Lancet; 2021 Mar; 397(10278):1023-1034. PubMed ID: 33587887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines.
    Painter C; Isaranuwatchai W; Prawjaeng J; Wee HL; Chua BWB; Huynh VA; Lou J; Goh FT; Luangasanatip N; Pan-Ngum W; Yi W; Clapham H; Teerawattananon Y
    Appl Health Econ Health Policy; 2021 Jul; 19(4):463-472. PubMed ID: 34235643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The costs of coronavirus vaccines and their pricing.
    Light DW; Lexchin J
    J R Soc Med; 2021 Nov; 114(11):502-504. PubMed ID: 34732097
    [No Abstract]   [Full Text] [Related]  

  • 12. Cash payments in Africa could boost vaccine uptake.
    Arezki R
    Nature; 2021 Aug; 596(7870):9. PubMed ID: 34345045
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why does the COVAX facility fail to bridge the 'immunization gap'?
    Shao Q
    J Public Health Policy; 2024 Mar; 45(1):126-136. PubMed ID: 38243069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equitable and Effective Distribution of the COVID-19 Vaccines - A Scientific and Moral Obligation.
    Binagwaho A; Mathewos K; Davis S
    Int J Health Policy Manag; 2022 Feb; 11(2):100-102. PubMed ID: 33949818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future.
    Pilkington V; Keestra SM; Hill A
    Front Public Health; 2022; 10():821117. PubMed ID: 35321196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing the global vaccine supply chain: balancing intellectual property rights with post COVID-19 vaccine equity.
    Park SP; Lee HJ; Yu Y; Lee EYJ; Park YS
    BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 38035734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who Will Pay for the COVID-19 Vaccines for Africa?
    Lucero-Prisno DE; Ogunkola IO; Imo UF; Adebisi YA
    Am J Trop Med Hyg; 2021 Jan; 104(3):794-796. PubMed ID: 33427194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccines pricing policy options for low-income and middle- income countries.
    Guzman J; Hafner T; Maiga LA; Giedion U
    BMJ Glob Health; 2021 Mar; 6(3):. PubMed ID: 33727281
    [No Abstract]   [Full Text] [Related]  

  • 20. Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC).
    Le Gargasson JB; Breugelmans JG; Mibulumukini B; Da Silva A; Colombini A
    Vaccine; 2013 Apr; 31(15):1886-91. PubMed ID: 23462529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.